Market Research Logo

US Regulatory Trends During 2010: A Rapidly Changing Environment

28 Pages BMI Research January 21, 2011 SKU: BMI6169372

A Rapidly Changing Environment Current Landscape The US Food and Drug Administration (FDA) approved 21 new molecular entities (NMEs) in 2010, the lowest since 18 new drugs were approved in 2007.

Despite this drop in registrations, BMI notes that five potential blockbusters received approval during 2010, highlighting promising revenue growth opportunities for the drugmakers concerned: Genentech, Novo Nordisk, Amgen, Novartis and Dendreon.

Of the potentially new blockbuster drugs approved, most are biological therapies, including Agmen’s Prolia (denosumab) to treat osteoporosis in menopausal women, Genentech’s Actemra (tocilizumab) to treat rheumatoid arthritis, and Dendreon’s Provenge (sipuleucel-T), an immunetherapy for prostate cancer.

Show Full Description

Show Table of Contents

US Regulatory Trends During 2010: A Rapidly Changing Environment

BMI Research
January 21, 2011

Search inside this report

Pricing & Delivery

Online Download

Didn't find what you are looking for?

Let us find it for you. One of our knowledgeable research assistants will work with you to find exactly the right research to answer your questions:

US: 800.298.5699 International: +1.240.747.3093 Or leave us a message and we'll call you back!

Receive bi-weekly email alerts for new market research.

CTA Image

Download our free eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download CTA

Share this report